Filtered By:
Condition: Arthritis
Infectious Disease: Herpes
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 31 results found since Jan 2013.
Herpes Zoster and the Risk for Stroke in Patients with Autoimmune Diseases
Conclusion: In patients with autoimmune diseases, incident HZ was associated with up to a two‐fold increased risk for stroke in the subsequent few months. These data provide urgency for developing strategies to reduce the risk of VZV. This article is protected by copyright. All rights reserved.
Source: Arthritis and Rheumatism - September 1, 2016 Category: Rheumatology Authors: L.H. Calabrese, F. Xie, H. Yun, K. Winthrop, J.W. Baddley, C. Calabrese, J.R. Curtis Tags: Full Length Source Type: research
Herpes Zoster and the Risk of Stroke in Patients With Autoimmune Diseases
ConclusionIn patients with autoimmune diseases, incident HZ was associated with as much as a 2‐fold increased risk of stroke in the subsequent few months. These data underscore the urgency of developing strategies for reducing the risk of varicella‐zoster virus.
Source: Arthritis and Rheumatism - January 27, 2017 Category: Rheumatology Authors: Leonard H. Calabrese, Fenglong Xie, Huifeng Yun, Kevin L. Winthrop, John W. Baddley, Cassandra Calabrese, Jeffrey R. Curtis Tags: Autoimmune Disease Source Type: research
Comparative Safety of BNT162b2 and mRNA-1273 Vaccines in a Nationwide Cohort of US Veterans
CONCLUSIONS AND RELEVANCE: The findings of this cohort study suggest that there were few differences in risk of adverse events within 14 days of the first dose of either the BNT162b2 or the mRNA-1273 vaccine and small-magnitude differences within 42 days of the first dose. The 38-week risks of adverse events were low in both vaccine groups, although risks were lower for recipients of the mRNA-1273 vaccine than for recipients of the BNT162b2 vaccine. Although the primary analysis was designed to detect safety events unrelated to SARS-CoV-2 infection, the possibility that these differences may partially be explained by a low...
Source: Herpes - June 13, 2022 Category: Infectious Diseases Authors: Barbra A Dickerman Arin L Madenci Hanna Gerlovin Katherine E Kurgansky Jessica K Wise Michael J Figueroa Mu ñiz Brian R Ferolito David R Gagnon J Michael Gaziano Kelly Cho Juan P Casas Miguel A Hern án Source Type: research
Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study
This study is active but not recruiting and is registered with ClinicalTrials.gov, number NCT02706951.FindingsPatients were screened between Feb 23, 2016, and May 19, 2017 and 648 were randomly assigned to treatment. 598 (92%) completed week 14. At week 14, an ACR20 response was achieved by 89 (41%) of 216 patients (95% CI 35–48) in the continued methotrexate group, 147 (68%) of 217 patients (62–74) receiving upadacitinib 15 mg, and 153 (71%) of 215 patients (65–77) receiving upadacitinib 30 mg (p<0·0001 for both doses vs continued methotrexate). DAS28(CRP) 3·2 or lower was met by 42 (19%) of 216 (95% CI 14–2...
Source: The Lancet - May 24, 2019 Category: General Medicine Source Type: research
Basis for diurnal exacerbation of neuropathic pain hypersensitivity and its application for drug development
J Biochem. 2021 Dec 30:mvab143. doi: 10.1093/jb/mvab143. Online ahead of print.ABSTRACTIn addition to diurnal rhythms in physiology and behavior, a variety of pathological conditions also exhibit marked day-night changes in symptom intensity, exemplified by allergic rhinitis, arthritis, asthma, myocardial infarction, congestive heart failure, stroke, and chronic pain disorders. Currently, novel therapeutic approaches are facilitated by the development of chemical compounds targeted to key proteins that cause diurnal exacerbation of pathological events. Neuropathic pain is a chronic condition that occurs by tumor-induced ne...
Source: Herpes - December 30, 2021 Category: Infectious Diseases Authors: Satoru Koyanagi Naoki Kusunose Sai Yasukochi Shigehiro Ohdo Source Type: research
The Importance of CXCL1 in Physiology and Noncancerous Diseases of Bone, Bone Marrow, Muscle and the Nervous System
Int J Mol Sci. 2022 Apr 11;23(8):4205. doi: 10.3390/ijms23084205.ABSTRACTThis review describes the role of CXCL1, a chemokine crucial in inflammation as a chemoattractant for neutrophils, in physiology and in selected major non-cancer diseases. Due to the vast amount of available information, we focus on the role CXCL1 plays in the physiology of bones, bone marrow, muscle and the nervous system. For this reason, we describe its effects on hematopoietic stem cells, myoblasts, oligodendrocyte progenitors and osteoclast precursors. We also present the involvement of CXCL1 in diseases of selected tissues and organs including A...
Source: Herpes - April 23, 2022 Category: Infectious Diseases Authors: Jan Korbecki Magdalena G ąssowska-Dobrowolska Jerzy W ójcik Iwona Szatkowska Katarzyna Barczak Miko łaj Chlubek Irena Baranowska-Bosiacka Source Type: research
Safety of JAK inhibitors: a real-life multicenter retrospective cohort study
CONCLUSION: Our real-life data confirm that JAKi are effective and carry a low risk of AESI, especially in patients that do not display cardiovascular risk factors at baseline. Our study could not identify differences between molecules and different profiles should be defined in larger prospective cohorts.PMID:37527867 | DOI:10.3899/jrheum.2023-0145
Source: Journal of Rheumatology - August 1, 2023 Category: Rheumatology Authors: Marco Lanzillotta Nicola Boffini Elisa Barone Gilberto Cincinelli Maria Chiara Gerardi Nicoletta Luciano Maria Manara Nicola Ughi Oscar Massimiliano Epis Carlo Selmi Roberto Felice Caporali Lorenzo Dagna Source Type: research
